-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| Industry | Biotechnology |
| ISIN | US0345691036 |
| Sector | Healthcare |
| PE Ratio | None |
|---|---|
| Target Price | 8 |
| Market Cap | 40M |
| Beta | -1.14 |
| Dividend Yield | None |
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ANEB using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025